State-of-the-art building approved for Oxford Science Park
A state-of-the-art laboratory building will be built at Oxford Science Park after city councillors gave it the go-ahead.The park secured planning permission for the four-storey building, which will be built close to the closed pub, The Priory, the Ozone Leisure Park and the Kassam Stadium, on Tuesday.The development will include 168 car parking spaces, electric charging points and just over 100 bike spaces.Yong Shen, the park's director, said the approval was "fantastic news" and will help it deliver more "world-class facilities in an established setting that promotes collaboration, sustainability and discovery".
The new building will sit on currently undeveloped land between the science park and the neighbouring cinema and bowling rink development.It will not involve any part of the Ozone Leisure Park, which is itself the subject of a different plan that could lead to its redevelopment.
You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
4 hours ago
- The Independent
Lord Sugar: Amstrad-inspired firm led by grandson ‘not relying on past glory'
Lord Alan Sugar has said the digital marketing agency run by his grandson and named after his famous brand Amstrad is not 'relying on past glory', as it counts the latest winner of The Apprentice among its clientele. The business mogul announced last year that he had bought back the rights to the household brand name and was launching Amstrad Digital. The firm is headed by his grandson Joe Baron, and Tom D'Arcy, who both worked at a rival agency, Climb Online, which was set up by The Apprentice winner Mark Wright. A year since launching, Essex-based Amstrad Digital has generated a turnover of around £600,000. This has partly been possible through projects with a raft of businesses under Lord Sugar's own portfolio – many of which stem from the BBC One boardroom-based reality series. They include the latest winner of the programme, Dean Franklin, who secured £250,000 of investment from Lord Sugar into the air conditioning business that he set up during the pandemic. Lord Sugar said Amstrad Digital was 'not just treading water' but was making money and 'laying down a foundation for serious long-term growth'. 'The brand still carries weight, and they're using that smartly – not just relying on past glory but backing it up with a solid service offering,' he told the PA news agency. 'From day one, Amstrad's always been about giving people value for money. 'No fluff, no overpriced nonsense – just a solid, affordable product that actually does what it says on the tin. 'That was the principle back in the 1980s, and I made sure we kept that at the heart of Amstrad Digital.' The businessman founded electronics company Amstrad in 1968, at the age of 21, selling audio and computer equipment before making the first range of Sky receivers and dishes. It was eventually sold for £125 million to the broadcasting giant, which still uses the software but not the brand name. After handing over the reins to his grandson, Lord Sugar said Mr Baron has a 'strong appetite for success', adding: 'I expect nothing less.' 'Joe being my grandson has not meant that he gets any handouts and exceptions when things get difficult,' he told PA. Mr Baron acknowledged uncertainty in the wider industry amid businesses making cutbacks on marketing spending, and concerns over the rapid growth of artificial intelligence (AI). He said the uncertainty was 'difficult' but an 'opportunity for us to set ourselves apart, which has been the aim since day one'. Earlier this month, digital marketing firm S4 Capital, which was founded by the former boss of WPP, said clients were remaining cautious about spending due to tougher economic conditions and uncertainty about global trade.
The Independent
4 hours ago
- The Independent
Why nightmares could make you age faster and die sooner
Frequent nightmares are linked to premature ageing and increase the risk of an early death, according to a new study. Adults who report weekly nightmares are more than three times likely to die before the age of 70 compared to those who rarely or never experience them, researchers found. The study found nightmares to be a 'stronger predictor of premature death' than smoking, obesity, poor diet, and low physical activity. The scientists warned the findings should be treated as a 'public health concern', but said people can reduce nightmares by managing stress. The team, led by Dr Abidemi Otaiku of the UK Dementia Research Institute, and Imperial College London, analysed data from 2,429 children aged eight to 10 and 183,012 adults aged 26 to 86 over a period of 19 years. The research, presented at the European Academy of Neurology (EAN) Congress this month, found that nightmares disrupt both sleep quality and duration, which impairs the body's overnight cellular restoration and repair ability. The combined impacts of chronic stress and disrupted sleep are likely to contribute to the accelerated ageing of our cells and bodies. Dr Otaiku said, 'Our sleeping brains cannot distinguish dreams from reality. That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake.' He said: 'Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process.' He added: 'Given how common and modifiable nightmares are, they should be taken far more seriously as a public health concern.' Researchers found that children and adults who had frequent nightmares also exhibited faster ageing. This accounted for approximately 40 per cent of those who had a higher risk of early death. Dr Otaiku said this was the first study to show nightmares can predict faster biological ageing and earlier mortality, even after accounting for other health issues. Even monthly nightmares were linked to faster ageing and increased mortality compared to those who had no nightmares. and the links were consistent across all ages, sexes, ethnicities, and mental health statuses. 'The good news is that nightmares can be prevented and treated,' said Dr Otaiku. Simple measures, such as maintaining good sleep hygiene, managing stress, seeking treatment for anxiety or depression and not watching scary films can be effective in reducing nightmares, he said.
The Independent
6 hours ago
- The Independent
The simple blood test that can predict Alzheimer's decline
Alzheimer 's decline could be predicted with a simple blood test already offered to those at risk of type 2 diabetes. The disease is the most common type of dementia, with symptoms including confusion, speech and language issues, problems with moving around and behaviour changes. Around a million people in the UK are living with dementia, but that figure is projected to rise to 1.4 million by 2040, Alzheimer's UK warns. There is currently no cure for the disease nor any definitive way to predict how quickly it will progress, only medicines to help relieve some of the symptoms. However, research presented at the European Academy of Neurology (EAN) Congress 2025 suggests a blood test used to detect insulin resistance could also identify patients at a high risk of cognitive decline. Neurologists at the University of Brescia, in Italy, analysed data from 315 non-diabetic patients with cognitive deficits – that included 200 people with Alzheimer's disease. All participants were tested for insulin resistance using the triglyceride-glucose (TyG) index – a low-cost, widely available marker calculated from standard blood test. They were then followed up three years later. Participants were divided into groups of varying cognitive impairment and also separated according to their insulin resistance score. Among those with mild cognitive impairment due to Alzheimer's, individuals with the highest TyG scores declined four times faster than those with lower TyG levels – but this link was not seen in the group with cognitive impairment not caused by Alzheimer's. 'Once mild cognitive impairment is diagnosed, families always ask how fast it will progress,' said lead investigator Dr Bianca Gumina. 'Our data show that a simple metabolic marker available in every hospital laboratory can help identify more vulnerable subjects who may be suitable candidates for targeted therapy or specific intervention strategies.' It's believed insulin resistance impairs glucose uptake in the brain, which means it is less active. This can lead to increased inflammation in the brain disrupting the blood-brain barrier and contributing to amyloid build-up – a protein that can form toxic plaques in the brain - all of which are linked with the progression of Alzheimer's disease. While inflammation is the body's defence mechanism which responds to damage and infection to keep us healthy, too much of a good thing can have consequences, Alzheimer's Research explains. When these toxic proteins build up in people with Alzheimer's, the brain fights back with an inflammatory response to keep the damage at bay. But this is thought to cause more damage. 'We were surprised to see the effect only in the Alzheimer's spectrum and not in other neurodegenerative diseases', Dr Gumina noted. She suggested it highlights that there is a 'disease-specific vulnerability' to insulin resistance and interventions could change the trajectory of the disease. Researchers also found high insulin resistance was associated with blood–brain barrier disruption and cardiovascular risk factors, but these were not associated with increased risk of Alzheimer's progression. It's hoped these findings could help detect Alzheimer's patients who are at a high-risk of cognitive decline early and enrol them in more targeted clinical trials – such as anti-amyloid trials. This blood test could also be used to make timely interventions to improve their insulin sensitivity. 'If targeting metabolism can delay progression, we will have a readily modifiable target that works alongside emerging disease-modifying drugs', concluded Dr Gumina. The researchers are currently investigating whether levels of insulin resistance also track with neuroimaging biomarkers- brain scans which indicate the structure, function and chemistry of the organ as well as diagnosing neurological conditions.
